FierceBiotech 2026년 5월 6일 Avalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind
Recursion 2026년 5월 6일 After a decade of hype, Najat Khan is bringing Recursion back down to earth - Fierce Biotech
Revvity 2026년 5월 6일 Revvity tops Q1 estimates and unveils plans to exit China immunodiagnostics - Indian Pharma Post
Agilent 2026년 5월 6일 Assessing Agilent Technologies (A) Valuation After FDA Approval Of PD L1 Assay For KEYTRUDA - Yahoo Finance
Novo Nordisk 2026년 5월 6일 ‘No change’ for CagriSema as Novo ditches single-chamber device - Fierce Biotech
Agilent 2026년 5월 6일 Assessing Agilent Technologies (A) Valuation After FDA Companion Diagnostic Approval For Esophageal Cancer - simplywall.st
Agilent 2026년 5월 6일 Assessing Agilent Technologies (A) Valuation After FDA Companion Diagnostic Approval For Esophageal Cancer - simplywall.st
Lonza News 2026년 5월 6일 Fine Chemicals Market Dominated by Europe | Lonza, Evonik, SRF Drive Pharma & Specialty Growth - openPR.com
Brady Corporation 2026년 5월 6일 Brady unveils cordless industrial label printing solution - African Review
Recursion 2026년 5월 6일 Recursion Pharmaceuticals Stock (RXRX) Opinions on Q1 2026 Earnings - Quiver Quantitative